Putrino Lab
@putrinolab.bsky.social
drive a path forward to FDA approval for folks with Long COVID to access the therapy. Huge thanks to my incredible team for driving this work forward and to Dr Skip Pridgen and Brian Corday who have been working day and night toward helping us get this to pwLC faster.
/end
/end
January 6, 2026 at 4:34 PM
drive a path forward to FDA approval for folks with Long COVID to access the therapy. Huge thanks to my incredible team for driving this work forward and to Dr Skip Pridgen and Brian Corday who have been working day and night toward helping us get this to pwLC faster.
/end
/end
announce that we have received an IND-exemption from the FDA to begin the larger, placebo-controlled trial of this regimen. This will allow us to capture objective biomarkers of responders and further understand who is most likely to respond to this regimen and, if successful,
2/
2/
January 6, 2026 at 4:34 PM
announce that we have received an IND-exemption from the FDA to begin the larger, placebo-controlled trial of this regimen. This will allow us to capture objective biomarkers of responders and further understand who is most likely to respond to this regimen and, if successful,
2/
2/
duration, high-dose approaches, not just a few days of a single drug. We didn’t have sufficient data to understand responder analysis in this case series but we will be launching a larger trial this year that will enable that. Here’s to starting off the year with some hope!
/end
/end
January 5, 2026 at 7:33 PM
duration, high-dose approaches, not just a few days of a single drug. We didn’t have sufficient data to understand responder analysis in this case series but we will be launching a larger trial this year that will enable that. Here’s to starting off the year with some hope!
/end
/end
combination antiviral and monoclonal therapies have a role in the treatment of #LongCOVID and other infection-associated chronic conditions and illnesses. But as @microbeminded2 and others showed us in their consensus statement it has to be long-
www.thelancet.com/journals/lan...
5/
www.thelancet.com/journals/lan...
5/
Lancet
https://thelancet.com/journals/lanin…
January 5, 2026 at 7:33 PM
combination antiviral and monoclonal therapies have a role in the treatment of #LongCOVID and other infection-associated chronic conditions and illnesses. But as @microbeminded2 and others showed us in their consensus statement it has to be long-
www.thelancet.com/journals/lan...
5/
www.thelancet.com/journals/lan...
5/
period was long: 600 days. In the Val/Cel + Pax group, functional improvements were sustained across the 600 days of follow-up.
These are encouraging findings that I think more than justify the need for a larger clinical trial and validate the expert consensus that
4/
These are encouraging findings that I think more than justify the need for a larger clinical trial and validate the expert consensus that
4/
January 5, 2026 at 7:33 PM
period was long: 600 days. In the Val/Cel + Pax group, functional improvements were sustained across the 600 days of follow-up.
These are encouraging findings that I think more than justify the need for a larger clinical trial and validate the expert consensus that
4/
These are encouraging findings that I think more than justify the need for a larger clinical trial and validate the expert consensus that
4/
The people who chose the latter reported greater benefit. 2) The subset of people who started with Val/Cel only but then chose to retry the protocol with Paxlovid added experienced more benefit with the three drugs together than they did with the two drugs
3) The follow-up
3/
3) The follow-up
3/
January 5, 2026 at 7:33 PM
The people who chose the latter reported greater benefit. 2) The subset of people who started with Val/Cel only but then chose to retry the protocol with Paxlovid added experienced more benefit with the three drugs together than they did with the two drugs
3) The follow-up
3/
3) The follow-up
3/
It is a small, open-label case series, but there are some interesting things that are worth noting that give me hope that what we are seeing is real and will hold up in a larger trial
1) People got to choose between Val/Cel only (called ‘IMC-2’ in the paper) and Val/Cel + Pax
2/
1) People got to choose between Val/Cel only (called ‘IMC-2’ in the paper) and Val/Cel + Pax
2/
January 5, 2026 at 7:33 PM
It is a small, open-label case series, but there are some interesting things that are worth noting that give me hope that what we are seeing is real and will hold up in a larger trial
1) People got to choose between Val/Cel only (called ‘IMC-2’ in the paper) and Val/Cel + Pax
2/
1) People got to choose between Val/Cel only (called ‘IMC-2’ in the paper) and Val/Cel + Pax
2/
that we are heading toward some meaningful and actionable answers in 2026. Let’s keep hope alive this year, but more importantly, let’s move with urgency to provide the answers that millions deserve.
/end
/end
January 1, 2026 at 5:54 PM
that we are heading toward some meaningful and actionable answers in 2026. Let’s keep hope alive this year, but more importantly, let’s move with urgency to provide the answers that millions deserve.
/end
/end
understanding is crucial to the development of general treatments that may help everyone a little vs. precision medicine targets that will help specific subtypes a lot. I’m grateful to the team of brilliant people I get to work with every day on these problems and hopeful
9/
9/
January 1, 2026 at 5:54 PM
understanding is crucial to the development of general treatments that may help everyone a little vs. precision medicine targets that will help specific subtypes a lot. I’m grateful to the team of brilliant people I get to work with every day on these problems and hopeful
9/
9/
the way that we test for pathogens and when we choose to treat them? These are fundamental questions that are crucial to our understanding of how various infection-associated chronic conditions and illnesses intersect and how they may differ completely. In turn, this
8/
8/
January 1, 2026 at 5:54 PM
the way that we test for pathogens and when we choose to treat them? These are fundamental questions that are crucial to our understanding of how various infection-associated chronic conditions and illnesses intersect and how they may differ completely. In turn, this
8/
8/
3) What is the dynamic nature of pathogen persistence? If we used the best assays to test people for a variety pathogens every single day how would hormonal, immune and general physiological fluctuations alter their pathogen testing results? Should this fundamentally change
7/
7/
January 1, 2026 at 5:54 PM
3) What is the dynamic nature of pathogen persistence? If we used the best assays to test people for a variety pathogens every single day how would hormonal, immune and general physiological fluctuations alter their pathogen testing results? Should this fundamentally change
7/
7/
antibody testing to understand this problem? I’m hoping that some of our antiviral/antibiotic (monotherapeutic and combination) trials that conclude in 2026, paired with our work with Francis Eun-Hyung Lee on her brilliant MENSA assay will help us to answer this question.
6/
6/
January 1, 2026 at 5:54 PM
antibody testing to understand this problem? I’m hoping that some of our antiviral/antibiotic (monotherapeutic and combination) trials that conclude in 2026, paired with our work with Francis Eun-Hyung Lee on her brilliant MENSA assay will help us to answer this question.
6/
6/
reactivated pathogens mean? If your IgG titers for pathogens such as Babesia, Borrelia, EBV, CMV, etc are through the roof, what action should be taken? If you can knock these antibody numbers back to normal, will we see clinical improvement? Is it time to go beyond simple
5/
5/
January 1, 2026 at 5:54 PM
reactivated pathogens mean? If your IgG titers for pathogens such as Babesia, Borrelia, EBV, CMV, etc are through the roof, what action should be taken? If you can knock these antibody numbers back to normal, will we see clinical improvement? Is it time to go beyond simple
5/
5/
how SARS-CoV-2 is problematically persisting in people with #LongCOVID and how it is asymptomatically (for now) persisting in healthy controls. My hope is that @polybioRF’s VIPER program will be instrumental in shining light on this in 2026.
2) What does testing positive for
4/
2) What does testing positive for
4/
January 1, 2026 at 5:54 PM
how SARS-CoV-2 is problematically persisting in people with #LongCOVID and how it is asymptomatically (for now) persisting in healthy controls. My hope is that @polybioRF’s VIPER program will be instrumental in shining light on this in 2026.
2) What does testing positive for
4/
2) What does testing positive for
4/
clinical problems that we face.
1) Why do some people test positive on certain persistence assays and negative on others? How can we use all of the commercially and scientifically available assays to create a unifying test for persistence that helps us to understand when and
3/
1) Why do some people test positive on certain persistence assays and negative on others? How can we use all of the commercially and scientifically available assays to create a unifying test for persistence that helps us to understand when and
3/
January 1, 2026 at 5:54 PM
clinical problems that we face.
1) Why do some people test positive on certain persistence assays and negative on others? How can we use all of the commercially and scientifically available assays to create a unifying test for persistence that helps us to understand when and
3/
1) Why do some people test positive on certain persistence assays and negative on others? How can we use all of the commercially and scientifically available assays to create a unifying test for persistence that helps us to understand when and
3/
hope we can answer this year. Since it isn’t my first time on the internet let me explicitly state: there are other questions that we will be chasing equally aggressively, but these are the ones that I most want to answer to up-level my own understanding of the scientific and
2/
2/
January 1, 2026 at 5:54 PM
hope we can answer this year. Since it isn’t my first time on the internet let me explicitly state: there are other questions that we will be chasing equally aggressively, but these are the ones that I most want to answer to up-level my own understanding of the scientific and
2/
2/
helper given your long history of good works. You clearly have a lot of fans in the disabled community, so please apologize and commit to doing better.
Walt Whitman never said it, but Ted Lasso definitely did:
“Be curious, not judgmental”.
🙏🏻
/end
Walt Whitman never said it, but Ted Lasso definitely did:
“Be curious, not judgmental”.
🙏🏻
/end
December 29, 2025 at 12:30 PM
helper given your long history of good works. You clearly have a lot of fans in the disabled community, so please apologize and commit to doing better.
Walt Whitman never said it, but Ted Lasso definitely did:
“Be curious, not judgmental”.
🙏🏻
/end
Walt Whitman never said it, but Ted Lasso definitely did:
“Be curious, not judgmental”.
🙏🏻
/end
There are many clinicians, patients, advocates and scientists here in NY, a city hit harder than most by #COVID and #LongCOVID, who would happily sit down and talk with you about this topic. I truly hope you choose to learn from this and help, because I do believe you to be a
8/
8/
December 29, 2025 at 12:30 PM
There are many clinicians, patients, advocates and scientists here in NY, a city hit harder than most by #COVID and #LongCOVID, who would happily sit down and talk with you about this topic. I truly hope you choose to learn from this and help, because I do believe you to be a
8/
8/
You have a loud voice, a big following and your actions have consequences. I sincerely hope that you might open yourself up to being educated about all the reasons that those two maskers that you always see are brave and stalwart enough to be continuing to mask in public.
7/
7/
December 29, 2025 at 12:30 PM
You have a loud voice, a big following and your actions have consequences. I sincerely hope that you might open yourself up to being educated about all the reasons that those two maskers that you always see are brave and stalwart enough to be continuing to mask in public.
7/
7/
done more than most in this space and it seems like you did it because you genuinely care for these folks. Given this, I hope I’m right that this moment on your @weeklyshowpodcast.bsky.social was a moment where you said something unkind because you are uninformed, not because you are cruel.
6/
6/
December 29, 2025 at 12:30 PM
done more than most in this space and it seems like you did it because you genuinely care for these folks. Given this, I hope I’m right that this moment on your @weeklyshowpodcast.bsky.social was a moment where you said something unkind because you are uninformed, not because you are cruel.
6/
6/
sensible to adopt masking as on of the few reliable ways to protect oneself and others when entering and sharing public spaces. I want to give you the benefit of the doubt rather than condemn you outright given your history of meaningful advocacy for 9/11 survivors. You have
5/
5/
December 29, 2025 at 12:30 PM
sensible to adopt masking as on of the few reliable ways to protect oneself and others when entering and sharing public spaces. I want to give you the benefit of the doubt rather than condemn you outright given your history of meaningful advocacy for 9/11 survivors. You have
5/
5/
just think that, until governments enact good-sense measures against the ongoing SARS-CoV-2 pandemic (I.e. air purifiers, better ventilation, routine testing, far UVC germicidal lights, development of post-exposure prophylaxis drugs and CURES for #LongCOVID), it is really
4/
4/
December 29, 2025 at 12:30 PM
just think that, until governments enact good-sense measures against the ongoing SARS-CoV-2 pandemic (I.e. air purifiers, better ventilation, routine testing, far UVC germicidal lights, development of post-exposure prophylaxis drugs and CURES for #LongCOVID), it is really
4/
4/